Showing 1 posts of 1 posts found.
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
Care Quality Commission appoints Emily Miles as Chief Executive
National survey aims to improve glaucoma care across the UK
Phase 3 trials support expanded use of Dysport for migraine prevention
Roche secures CE Mark for automated latent tuberculosis blood test
ReproNovo Phase 2 fertility study doses first participant